CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $85.00 at Bank of America
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
Brokers Issue Forecasts for CRSP FY2024 Earnings
Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...
STAT4d
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Pharmaceutical Technology46m
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Crispr Therapeutics price target lowered to $85 from $98 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.
Business Insider5d
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
3 Mid-Cap Stocks That Could Take Off in 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...
Benzinga.com6d
Check Out What Whales Are Doing With CRSP
High-rolling investors have positioned themselves bullish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through ...